Back Login to subscribe 🔔 Set Alert

TLSA Tiziana Life Sciences Ltd. Common Shares

Sector: Healthcare
Industry: Biotechnology
15 min delay
Today's News Sentiment
Loading...
Upcoming Earnings
Loading...
TLSA Fundamental Data
Loading...
Similar Companies
Loading...
TLSA Options Chain
Put/Call Ratio
-
-
Expected Move
-
-
Max Pain
-
-
ATM Call Break-even
-
-
ATM Put Break-even
-
-
Loading options…
CALLS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
PUTS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
TLSA Insider Transactions
Loading insider data…
TLSA News
Date Headline Sentiment
Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027
63.09%
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
95.63%
Tiziana Life Sciences shares are trading higher after the company announced that it has submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy.
94.45%
Tiziana Life Sciences Announces Submission Of FDA Orphan Drug Designation Request For Foralumab In Multiple System Atrophy
85.3%
Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial
77.23%
Tiziana Completes Phase 2a MS Trial, Topline Data Due In October
62.09%
Why Is Tiziana Life Sciences Stock Gaining Thursday?
82.21%
Tiziana Life Sciences shares are trading higher after the company announced the signing of a a Memorandum of Understanding with the King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to collaborate on a clinical trial evaluating a combination of the proprietary intranasal foralumab and existing anti-CD20 therapy in patients with relapsing-remitting multiple sclerosis who are responding poorly to anti-CD20 therapy alone.
95.27%
12 Health Care Stocks Moving In Thursday's Pre-Market Session
96.06%
Tiziana Life Sciences Announces MOU With King Abdullah International Medical Research Center And Foundation For Neurologic Diseases For Trial Of Intranasal Foralumab With Anti-CD20 Therapy In Relapsing-Remitting MS
90.32%